Thai Huu Ho

List of Publications by Year
in descending order

73 papers	8,721 citations	126907 33 h-index	79698 73 g-index
79 all docs	79 docs citations	79 times ranked	12895 citing authors

#	Article	IF	Citations
1	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell, 2017, 171, 540-556.e25.	28.9	1,742
2	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 135-145.	27.0	1,040
3	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	12.6	898
4	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	6.4	523
5	Muscleblind proteins regulate alternative splicing. EMBO Journal, 2004, 23, 3103-3112.	7.8	438
6	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Reports, 2016, 14, 2476-2489.	6.4	298
7	Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Human Molecular Genetics, 2005, 14, 1539-1547.	2.9	218
8	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research, 2015, 21, 1071-1077.	7.0	217
9	The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science, 2016, 352, 1344-1348.	12.6	211
10	Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell, 2016, 166, 950-962.	28.9	204
11	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	7.0	193
12	Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy. Journal of Cell Science, 2005, 118, 2923-2933.	2.0	168
13	Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Research, 2014, 24, 241-250.	5.5	160
14	PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunology Research, 2015, 3, 1303-1307.	3.4	135
15	Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with lowâ€risk clear cell renal cell carcinoma. Cancer, 2014, 120, 1059-1067.	4.1	129
16	The mechanism of inhibition of Ran-dependent nuclear transport by cellular ATP depletion. Journal of Cell Biology, 2002, 157, 963-974.	5.2	116
17	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Antiâ€“PD-1 Therapies in Metastatic Melanoma. Clinical Cancer Research, 2018, 24, 5250-5260.	7.0	116
18	Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression. Journal of Urology, 2016, 195, 180-187.	0.4	113

#	Article	IF	Citations
19	Inhibition of intracellular lipolysis promotes human cancer cell adaptation to hypoxia. ELife, 2017, 6, .	6.0	104
20	Chromosome 3p Lossâ€“Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 3533-3539.	1.6	99
21	Distinct and overlapping control of 5-methylcytosine and 5-hydroxymethylcytosine by the TET proteins in human cancer cells. Genome Biology, 2014, 15, R81.	9.6	91
22	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	12.8	84
23	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Modern Pathology, 2016, 29, 34-42.	5.5	55
24	Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. European Urology, 2017, 71, 979-985.	1.9	52
25	Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. Oncotarget, 2016, 7, 1927-1946.	1.8	52
26	DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas. Clinical Cancer Research, 2016, 22, 6236-6246.	7.0	47
27	Macrophage HIF-1Î± Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research, 2020, 26, 4970-4982.	7.0	45
28	Ebselen inhibits QSOX1 enzymatic activity and suppresses invasion of pancreatic and renal cancer cell lines. Oncotarget, 2015, 6, 18418-18428.	1.8	45
29	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, e969-e975.	1.9	41
30	Loss of PBRM1 and BAP1 expression is less common in nonâ€“clear cell renal cell carcinoma than in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 23.e9-23.e14.	1.6	40
31	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. European Urology Focus, 2016, 2, 204-209.	3.1	40
32	Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2013, 1, 378-385.	3.4	37
33	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 820-824.	4.9	36
34	Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma. Cancer Research, 2015, 75, 316-329.	0.9	34
35	Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2017, 35, 3706-3713.	1.6	34
36	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. Scientific Reports, 2016, 6, 25.	3.3	32

#	Article	IF	Citations
37	Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncology, 2011, 7, 1247-1253.	2.4	28
38	Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. Journal of Proteome Research, 2019, 18, 331-340.	3.7	27
39	Genetic Kidney Cancer Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1347-1355.	4.9	26
40	BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor. BMC Urology, 2017, 17, 19.	1.4	26
41	The Impact of Pazopanib on the Cardiovascular System. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 387-398.	2.0	24
42	Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardio-Oncology, 2017, 3, .	1.7	23
43	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
44	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. Scientific Reports, 2020, 10, 701.	3.3	21
45	Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, Î²1â€“4 Branching, Î²1â€“6 Branching, and Î±2â€“6 Sialylation in Cancer. Journal of Proteome Research, 2018, 17, 543-558.	3.7	19
46	Behavior of blood plasma glycan features in bladder cancer. PLoS ONE, 2018, 13, e0201208.	2.5	19
47	Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 479-483.	3.9	18
48	Detection of tumor-associated cells in cryopreserved peripheral blood mononuclear cell samples for retrospective analysis. Journal of Translational Medicine, 2016, 14, 198.	4.4	17
49	Concordance of PDâ€1 and PDâ€L1 (B7â€H1) in paired primary and metastatic clear cell renal cell carcinoma. Cancer Medicine, 2020, 9, 1152-1160.	2.8	17
50	Molecular Inhibitor of QSOX1 Suppresses Tumor Growth In Vivo. Molecular Cancer Therapeutics, 2020, 19, 112-122.	4.1	17
51	The impact of FGFR1 and FRS2Î± expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer, 2015, 15, 304.	2.6	16
52	ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factorâ€“activated cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
53	Assessing the clinical use of clear cell renal cell carcinoma molecular subtypes identified by RNA expression analysis1These authors contributed equally to the writing of this article.. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 68.e17-68.e23.	1.6	10
54	A Multidisciplinary Biospecimen Bank of Renal Cell Carcinomas Compatible with Discovery Platforms at Mayo Clinic, Scottsdale, Arizona. PLoS ONE, 2015, 10, e0132831.	2.5	9

#	Article	IF	Citations
55	A Study of Combination Bicalutamide and Raloxifene for Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 196-202.e1.	1.9	9
56	In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma. Cancer Medicine, 2019, 8, 5760-5768.	2.8	8
57	Identification of DNA methylation signatures associated with poor outcome in lower-risk Stage, Size, Grade and Necrosis (SSIGN) score clear cell renal cell cancer. Clinical Epigenetics, 2021, 13, 12.	4.1	8
58	Validation of Gene Expression Signatures to Identify Low-risk Clear-cell Renal Cell Carcinoma Patients at Higher Risk for Disease-related Death. European Urology Focus, 2016, 2, 608-615.	3.1	7
59	Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors. Journal of Clinical Ultrasound, 2016, 44, 221-230.	0.8	7
60	Simple Mimetics of a Nuclear Localization Signal (NLS). Organic Letters, 2003, 5, 2437-2440.	4.6	6
61	Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). Oncologist, 2021, 26, 560-e1103.	3.7	6
62	Pazopanib for renal cell carcinoma leads to elevated mean arterial pressures in a murine model. Clinical and Experimental Hypertension, 2018, 40, 524-533.	1.3	5
63	Evolving Natural History of Metastatic Prostate Cancer. Cureus, 2020, 12, e11484.	0.5	4
64	The impact of genetic aberrations on response to radiumâ€223 treatment for castrationâ€resistant prostate cancer with bone metastases. Prostate, 2022, 82, 1202-1209.	2.3	4
65	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. Clinical Genitourinary Cancer, 2017, 15, e727-e734.	1.9	3
66	Outcome prediction following radical nephroureterectomy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 133.e9-133.e16.	1.6	3
67	Lgr5-positive endothelial progenitor cells occupy a tumor and injury prone niche in the kidney vasa recta. Stem Cell Research, 2020, 46, 101849.	0.7	2
68	Identification of a CD4+ T cell line with Treg-like activity. Human Immunology, 2022, 83, 281-294.	2.4	2
69	Phase Ib Study of Atezolizumab Plus Interferon-Î± with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Current Oncology, 2021, 28, 5466-5479.	2.2	2
70	8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness. BMC Urology, 2020, 20, 173.	1.4	1
71	Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology, 2012, 30, 368-368.	1.6	1
72	MicroRNA Expression in Clear Cell Renal Cell Carcinoma Cell Lines and Tumor Biopsies: Potential Therapeutic Targets. International Journal of Molecular Sciences, 2022, 23, 5604.	4.1	1

#	Article	IF	Citations
73	Abstract 1035: SETD2, a histone methyltransferase, is misregulated in advanced clear cell renal cell carcinoma (ccRCC). , 2012, , .		0